US market easily swallows AbbVie’s $14.7bn monster
A new megalith was plonked down on the US bond landscape on Monday when AbbVie, the branded pharmaceuticals business being spun off by Abbott Laboratories, sold a $14.7bn six-tranche deal that in some observers’ eyes was the biggest US corporate issue ever.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: